A high-fidelity simulation mannequin to introduce pharmacy students to advanced cardiovascular life support.
OBJECTIVE
To design and implement an advanced cardiac life support (ACLS) workshop featuring a human patient simulator (HPS) for third-year pharmacy students.


METHODS
The ACLS workshop consisted of a pre-session lecture, a calculation exercise, and a 40-minute ACLS session using an HPS. Twenty-four 5-member teams of students were assigned roles on a code team and participated in a ventricular fibrillation/pulseless ventricular tachycardia case.


RESULTS
Students completed an anonymous postactivity survey instrument and knowledge quiz. Most students who completed the ACLS workshop agreed they would like to participate in additional simulation activities and that the HPS experience enhanced their understanding of ACLS and the pharmacist responsibilities during an ACLS event (99.2% and 98.3%, respectively). However, the median score on the knowledge-based questions was 25%.


CONCLUSIONS
Pharmacy students agreed HPS enhanced their learning experience; however, their retention of the knowledge learned was not consistent with the perceived benefits of HPS to education.
Mieure
Katherine D
KD
Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, 789 South Limestone Street, Lexington, Kentucky, USA.
Vincent
William R
WR
Cox
Mark R
MR
Jones
Mikael D
MD
D022561:Advanced Cardiac Life Support / Q000193:education*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002983:Clinical Competence; D003198:Computer Simulation; D003194:Computer-Assisted Instruction; D054796:Drug Dosage Calculations; D004512:Education, Pharmacy / Q000379:methods*; D057209:Hospital Rapid Response Team; D006801:Humans; D007858:Learning; D008348:Manikins; D018794:Problem-Based Learning / Q000379:methods; D015397:Program Evaluation; D017180:Tachycardia, Ventricular / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D014693:Ventricular Fibrillation / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy
D000889:Anti-Arrhythmia Agents; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents